Outcomes following front-line chemotherapy in peripheral T-cell lymphoma: 10-year experience at The Royal Marsden and The Christie Hospital.
Loading...
Embargo End Date
ICR Authors
Authors
Gleeson, M
Peckitt, C
Cunningham, D
Gibb, A
Hawkes, EA
Back, M
Yasar, B
Foley, K
Lee, R
Dash, J
Johnson, H
O'Hara, C
Wotherspoon, A
Attygalle, A
Menasce, L
Shenjere, P
Potter, M
Ethell, ME
Dearden, C
Radford, J
Chau, I
Linton, K
Peckitt, C
Cunningham, D
Gibb, A
Hawkes, EA
Back, M
Yasar, B
Foley, K
Lee, R
Dash, J
Johnson, H
O'Hara, C
Wotherspoon, A
Attygalle, A
Menasce, L
Shenjere, P
Potter, M
Ethell, ME
Dearden, C
Radford, J
Chau, I
Linton, K
Document Type
Journal Article
Date
2018-07-03
Date Accepted
Abstract
We evaluated the outcomes for patients with peripheral T-cell lymphoma (PTCL) undergoing front-line chemotherapy at our institutions between 2002 and 2012. One hundred and fifty-six patients were eligible, comprising PTCL not otherwise specified (NOS) (n = 50, 32.0%), angioimmunoblastic T-cell lymphoma (AITL) (n = 44, 28.2%), anaplastic large-cell lymphoma (ALCL) ALK negative (n = 23, 14.7%), ALCL ALK positive (n = 16, 10.3%), and other (n = 23, 14.7%). Most patients received CHOP (66.0%) and 13.0% received an autologous hematopoietic progenitor cell transplant (HPCT). With a median follow-up of 63.4 months, 5-year overall survival (OS) and progression-free survival (PFS) was 38.8% and 19.8% respectively. Independent risk factors for inferior OS were age >60 years, International Prognostic Index (IPI) ≥ 2 and lack of complete response to induction. When responding patients were compared by receipt of an autologous HPCT versus not, HPCT was associated with improved PFS (p = .001) and OS (p = .046) and remained significant for PFS in multivariate analysis suggesting a possible therapeutic benefit.
Citation
Leukemia & lymphoma, 2018, 59 (7), pp. 1586 - 1595
Source Title
Publisher
TAYLOR & FRANCIS LTD
ISSN
1042-8194
eISSN
1029-2403
Collections
Research Team
Medicine (RMH Smith Cunningham)